• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

芬兰高危地区冠心病患者二级预防的结果。

Outcomes of Secondary Prevention among Coronary Heart Disease Patients in a High-Risk Region in Finland.

机构信息

Department of Geographical and Historical Studies, University of Eastern Finland, 80101 Joensuu, Finland.

North Karelia Hospital District, 80210 Joensuu, Finland.

出版信息

Int J Environ Res Public Health. 2018 Apr 11;15(4):724. doi: 10.3390/ijerph15040724.

DOI:10.3390/ijerph15040724
PMID:29641497
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5923766/
Abstract

Despite comprehensive national treatment guidelines, goals for secondary prevention of coronary heart disease (CHD) have not been sufficiently met everywhere in Finland. We investigated the recorded risk factor rates of CHD and their spatial differences in North Karelia Hospital District, which has a very high cardiovascular burden, in order to form a general view of the state of secondary prevention in a high-risk region. Appropriate disease codes of CHD-diagnoses and coding for percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) were used to identify from the electronic patient records the patient group eligible for secondary prevention. The cumulative incidence rate of new patients ( = 2556) during 2011-2014 varied from 1.9% to 3.5% between municipalities. The success in secondary prevention of CHD was assessed using achievement of treatment targets as defined in national guidelines. Health centres are administrated by municipalities whereupon the main reporting units were municipalities, together with composed classification of patients by age, gender and dwelling location. Health disparities between municipalities, settlement types and patient groups were found and are interpreted. Moreover, spatial high-risk and low-risk clusters of acute CHD were detected. The proportion of patients achieving the treatment targets of low-density lipoprotein cholesterol (LDL-C) varied from 21% to 38% between municipalities. Variation was also observed in the follow-up of patients; e.g., the rate of follow-up measurements of LDL-C in municipalities varied from 72% to 86%. Spatial variation in patients' sociodemographic and neighbourhood characteristics and morbidity burden partly explain the differences in outcomes, but there are also very likely differences in the care process between municipalities which requires a study in its own right.

摘要

尽管有全面的国家治疗指南,但芬兰各地在冠心病(CHD)二级预防目标方面仍未得到充分实现。我们调查了北卡累利阿医院区(CHD 心血管负担非常高)记录的 CHD 风险因素率及其空间差异,以便对高风险地区二级预防的状况形成总体看法。使用适当的 CHD 诊断疾病代码和经皮冠状动脉介入治疗(PCI)和冠状动脉旁路移植术(CABG)的编码,从电子病历中确定符合二级预防条件的患者群体。2011-2014 年期间新患者(=2556)的累积发病率在各城市之间从 1.9%到 3.5%不等。根据国家指南定义的治疗目标评估 CHD 二级预防的成功情况。健康中心由城市管理,主要报告单位是城市,同时按年龄、性别和居住地点对患者进行综合分类。发现并解释了城市之间、定居类型和患者群体之间的健康差异。此外,还检测到急性 CHD 的空间高危和低危集群。达到低密度脂蛋白胆固醇(LDL-C)治疗目标的患者比例在各城市之间从 21%到 38%不等。患者随访方面也存在差异;例如,各城市 LDL-C 随访测量率从 72%到 86%不等。患者社会人口统计学和邻里特征以及发病负担的空间变化部分解释了结果的差异,但城市之间的护理过程也可能存在差异,这需要进行独立研究。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5da4/5923766/a4c14f724d0e/ijerph-15-00724-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5da4/5923766/0e468b201849/ijerph-15-00724-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5da4/5923766/e9fe2d6b64b6/ijerph-15-00724-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5da4/5923766/c33965c3d775/ijerph-15-00724-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5da4/5923766/529092b7280c/ijerph-15-00724-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5da4/5923766/47694c30354f/ijerph-15-00724-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5da4/5923766/a4c14f724d0e/ijerph-15-00724-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5da4/5923766/0e468b201849/ijerph-15-00724-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5da4/5923766/e9fe2d6b64b6/ijerph-15-00724-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5da4/5923766/c33965c3d775/ijerph-15-00724-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5da4/5923766/529092b7280c/ijerph-15-00724-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5da4/5923766/47694c30354f/ijerph-15-00724-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5da4/5923766/a4c14f724d0e/ijerph-15-00724-g006.jpg

相似文献

1
Outcomes of Secondary Prevention among Coronary Heart Disease Patients in a High-Risk Region in Finland.芬兰高危地区冠心病患者二级预防的结果。
Int J Environ Res Public Health. 2018 Apr 11;15(4):724. doi: 10.3390/ijerph15040724.
2
Suboptimal achievement of low-density lipoprotein cholesterol targets in French patients with coronary heart disease. Contemporary data from the DYSIS II ACS/CHD study.法国冠心病患者低密度脂蛋白胆固醇目标未达最佳水平。来自DYSIS II ACS/CHD研究的当代数据。
Arch Cardiovasc Dis. 2017 Mar;110(3):167-178. doi: 10.1016/j.acvd.2016.11.004. Epub 2017 Feb 13.
3
Lipoprotein (a) and coronary heart disease - is there an efficient secondary prevention?脂蛋白(a)与冠心病——是否存在有效的二级预防措施?
Clin Res Cardiol Suppl. 2017 Mar;12(Suppl 1):18-21. doi: 10.1007/s11789-017-0088-x.
4
Statin initiation following coronary artery bypass grafting: outcome of a hospital discharge protocol.冠状动脉搭桥术后开始使用他汀类药物:出院方案的结果
Chest. 2005 Feb;127(2):455-63. doi: 10.1378/chest.127.2.455.
5
A long-term follow-up study of serum lipid levels and coronary heart disease in the elderly.老年人血脂水平与冠心病的长期随访研究
Chin Med J (Engl). 2004 Feb;117(2):163-7.
6
Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries--Findings from the EUROASPIRE IV survey.来自24个欧洲国家的冠心病患者的降脂药物治疗——EUROASPIRE IV调查结果
Atherosclerosis. 2016 Mar;246:243-50. doi: 10.1016/j.atherosclerosis.2016.01.018. Epub 2016 Jan 13.
7
Comparison of Secondary Prevention Status between Percutaneous Coronary Intervention and Coronary Artery Bypass Patients.经皮冠状动脉介入治疗与冠状动脉旁路移植术患者二级预防状况的比较。
Arq Bras Cardiol. 2017 Nov;109(5):466-474. doi: 10.5935/abc.20170153.
8
Application of the MAT-CHDSP to assess guideline adherence and therapy goal achievement in secondary prevention of coronary heart disease after percutaneous coronary intervention.应用 MAT-CHDSP 评估经皮冠状动脉介入治疗后冠心病二级预防中的指南依从性和治疗目标达标情况。
Eur J Clin Pharmacol. 2013 Mar;69(3):703-9. doi: 10.1007/s00228-012-1402-7. Epub 2012 Sep 19.
9
Role of depression in secondary prevention of Chinese coronary heart disease patients receiving percutaneous coronary intervention.抑郁症在接受经皮冠状动脉介入治疗的中国冠心病患者二级预防中的作用。
PLoS One. 2017 Dec 21;12(12):e0187016. doi: 10.1371/journal.pone.0187016. eCollection 2017.
10
Prevalence of low high-density lipoprotein cholesterol in patients with documented coronary heart disease or risk equivalent and controlled low-density lipoprotein cholesterol.已确诊冠心病或风险等同情况且低密度脂蛋白胆固醇得到控制的患者中低高密度脂蛋白胆固醇的患病率。
Am J Cardiol. 2007 Nov 15;100(10):1499-501. doi: 10.1016/j.amjcard.2007.06.058. Epub 2007 Sep 27.

引用本文的文献

1
Risk-stratified analysis of long-term clinical outcomes and cumulative costs in Finnish patients with recent acute coronary syndrome or coronary revascularization: a 5-year real-world study using electronic health records.芬兰近期急性冠状动脉综合征或冠状动脉血运重建患者长期临床结局和累积费用的风险分层分析:一项使用电子健康记录的5年真实世界研究
Eur Heart J Open. 2024 Jun 18;4(4):oeae049. doi: 10.1093/ehjopen/oeae049. eCollection 2024 Jul.
2
Effect of nursing intervention based on Maslow's hierarchy of needs in patients with coronary heart disease interventional surgery.基于马斯洛需求层次理论的护理干预对冠心病介入手术患者的影响。
World J Clin Cases. 2021 Nov 26;9(33):10189-10197. doi: 10.12998/wjcc.v9.i33.10189.
3

本文引用的文献

1
Geographic access to interventional cardiology services in one rural state.某农业州介入心脏病学服务的地理可及性
Heart Lung. 2016 Sep-Oct;45(5):434-40. doi: 10.1016/j.hrtlng.2016.07.002. Epub 2016 Aug 1.
2
Multimorbidity in chronic disease: impact on health care resources and costs.慢性病中的多重疾病:对医疗资源和成本的影响。
Risk Manag Healthc Policy. 2016 Jul 5;9:143-56. doi: 10.2147/RMHP.S97248. eCollection 2016.
3
Time Trends in Lifestyle, Risk Factor Control, and Use of Evidence-Based Medications in Patients With Coronary Heart Disease in Europe: Results From 3 EUROASPIRE Surveys, 1999-2013.
Compliance to secondary prevention strategies for coronary artery disease: a hospital-based cross-sectional survey from Ernakulam, South India.
冠心病二级预防策略的依从性:一项来自印度南部埃尔讷古勒姆的基于医院的横断面调查。
BMJ Open. 2020 Oct 10;10(10):e037618. doi: 10.1136/bmjopen-2020-037618.
欧洲冠心病患者生活方式、风险因素控制和循证药物使用的时间趋势:来自 3 项 EUROASPIRE 调查的结果,1999-2013 年。
Glob Heart. 2017 Dec;12(4):315-322.e3. doi: 10.1016/j.gheart.2015.11.003. Epub 2016 Mar 16.
4
The gender gap in risk factor control: Effects of age and education on the control of cardiovascular risk factors in male and female coronary patients. The EUROASPIRE IV study by the European Society of Cardiology.危险因素控制方面的性别差异:年龄和教育程度对男性和女性冠心病患者心血管危险因素控制的影响。欧洲心脏病学会的EUROASPIRE IV研究。
Int J Cardiol. 2016 Apr 15;209:284-90. doi: 10.1016/j.ijcard.2016.02.015. Epub 2016 Feb 3.
5
Using Electronic Health Records for Population Health Research: A Review of Methods and Applications.利用电子健康记录进行人群健康研究:方法与应用综述。
Annu Rev Public Health. 2016;37:61-81. doi: 10.1146/annurev-publhealth-032315-021353. Epub 2015 Dec 11.
6
Do the classification of areas and distance matter to the assessment results of achieving the treatment targets among type 2 diabetes patients?对于2型糖尿病患者而言,区域分类和距离对治疗目标达成的评估结果有影响吗?
Int J Health Geogr. 2015 Sep 30;14:27. doi: 10.1186/s12942-015-0020-x.
7
Primary care organisational interventions for secondary prevention of ischaemic heart disease: a systematic review and meta-analysis.缺血性心脏病二级预防的基层医疗组织干预措施:系统评价与荟萃分析
Br J Gen Pract. 2015 Jul;65(636):e460-8. doi: 10.3399/bjgp15X685681.
8
Determinants for achieving the LDL-C target of lipid control for secondary prevention of cardiovascular events in Taiwan.台湾地区心血管事件二级预防中实现血脂控制低密度脂蛋白胆固醇(LDL-C)目标的决定因素。
PLoS One. 2015 Mar 10;10(3):e0116513. doi: 10.1371/journal.pone.0116513. eCollection 2015.
9
EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries.欧洲动脉粥样硬化调查项目IV:欧洲心脏病学会对来自24个欧洲国家的冠心病患者的生活方式、危险因素及治疗管理情况的调查。
Eur J Prev Cardiol. 2016 Apr;23(6):636-48. doi: 10.1177/2047487315569401. Epub 2015 Feb 16.
10
Readiness for smoking cessation in coronary heart disease patients across Europe: Results from the EUROASPIRE III survey.欧洲冠心病患者戒烟准备度:来自 EUROASPIRE III 调查的结果。
Eur J Prev Cardiol. 2015 Sep;22(9):1212-9. doi: 10.1177/2047487314564728. Epub 2014 Dec 16.